A Longitudinal Study in Parkinson's Disease (PD) Patients

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified November 2012 by Tel-Aviv Sourasky Medical Center
Sponsor:
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01730599
First received: October 22, 2012
Last updated: November 15, 2012
Last verified: November 2012

October 22, 2012
November 15, 2012
November 2012
June 2015   (final data collection date for primary outcome measure)
change from baseline in updrs motor and total scores [ Time Frame: the participants will be followed for 5 years. the measurements will be taken evry 18 month. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01730599 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Longitudinal Study in Parkinson's Disease (PD) Patients
A Longitudinal 5 Years Follow up Study in Parkinson's Disease (PD) Patients Carriers of the LRRK2 Gene G2019S Mutation

This is a longitudinal study in patients with Parkinson's Disease (PD) carriers of a genetic mutation - substitution of gly with ser in position 2019 (G2019S) in the leucine-rich repeat kinase 2 (LRRK2) gene. The purpose of this study is to explore the association between genetic mutations in the known genes and their influence on disease manifestation over few years of follow up

Not Provided
Observational
Observational Model: Cohort
Not Provided
Not Provided
Non-Probability Sample

PD patients carriers of the G2019S mutation in the LRRK2 gene

Parkinson's Disease
Other: neurological exam
motor and cognitive functions
PD patients
PD patients carriers of the G2019S mutation in the LRRK2 gene
Intervention: Other: neurological exam
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
200
Not Provided
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • parkinson'd disease patients that already participated in a pasr cross sectional study

Exclusion Criteria:

  • subjects with cognitive decline by the parameters defined in Diagnostic and Statistical Manual of Mental Disorders (DSM)- IV
  • subjects with psychiatric disorder
  • subjects unable to sign a consent form
Both
30 Years and older
No
Contact: Anat Mirelman, PhD 972-3-6973014 anatmi@tasmc.health.gov.il
Israel
 
NCT01730599
TASMC-11-NG-0473
No
Tel-Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
Not Provided
Not Provided
Tel-Aviv Sourasky Medical Center
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP